Universal Beteiligungs und Servicegesellschaft mbH Takes $13.08 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 146,219 shares of the medical equipment provider's stock, valued at approximately $13,081,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.21% of Lantheus at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Kestra Investment Management LLC purchased a new position in Lantheus during the 4th quarter worth approximately $27,000. Summit Securities Group LLC purchased a new position in Lantheus during the 4th quarter worth approximately $37,000. Parkside Financial Bank & Trust increased its holdings in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. 1620 Investment Advisors Inc. purchased a new position in shares of Lantheus during the 4th quarter valued at approximately $125,000. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Lantheus during the 4th quarter valued at approximately $136,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Performance

Lantheus stock traded up $0.36 during trading on Tuesday, reaching $77.49. The company had a trading volume of 240,069 shares, compared to its average volume of 989,869. The firm's 50-day simple moving average is $91.65 and its 200 day simple moving average is $91.81. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The firm has a market capitalization of $5.36 billion, a PE ratio of 12.89 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the business posted $1.69 EPS. Lantheus's revenue was up .8% compared to the same quarter last year. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LNTH shares. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Finally, Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.